Market Research Logo

Cancer Cachexia - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Cancer Cachexia Overview
Therapeutics Development
Pipeline Products for Cancer Cachexia - Overview
Pipeline Products for Cancer Cachexia - Comparative Analysis
Cancer Cachexia - Therapeutics under Development by Companies
Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes
Cancer Cachexia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Cancer Cachexia - Products under Development by Companies
Cancer Cachexia - Products under Investigation by Universities/Institutes
Cancer Cachexia - Companies Involved in Therapeutics Development
Acacia Pharma Limited
Aeterna Zentaris Inc.
Amgen Inc.
Aphios Corporation
Atara Biotherapeutics, Inc.
Eli Lilly and Company
GTx, Inc.
Helsinn Healthcare S.A.
Incyte Corporation
KAEL-GemVax Co., Ltd.
Novartis AG
Obexia AG
PsiOxus Therapeutics Limited
Radius Health, Inc.
RaQualia Pharma Inc.
Rhythm Pharmaceuticals
Vicus Therapeutics, LLC
Viking Therapeutics, Inc.
Cancer Cachexia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(etodolac + propranolol hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(formoterol fumarate + megestrol acetate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-1889 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Antagonize ActRIIB for Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enobosarm - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Espindolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EXT-400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
landogrozumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia and Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NBD Peptide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OBX-1201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD-140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00432933 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Cancer Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cancer Cachexia - Recent Pipeline Updates
Cancer Cachexia - Dormant Projects
Cancer Cachexia - Discontinued Products
Cancer Cachexia - Product Development Milestones
Featured News & Press Releases
Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
Oct 24, 2013: GTx Presents Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer
Mar 14, 2013: GTx Announces Publication Of Enobosarm Phase II Trial Results In The Lancet Oncology
Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102
Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
Jun 25, 2012: GTx Announces Presentation On Enobosarm’s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cancer Cachexia, H2 2015
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Cancer Cachexia - Pipeline by Acacia Pharma Limited, H2 2015
Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2015
Cancer Cachexia - Pipeline by Amgen Inc., H2 2015
Cancer Cachexia - Pipeline by Aphios Corporation, H2 2015
Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2015
Cancer Cachexia - Pipeline by GTx, Inc., H2 2015
Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2015
Cancer Cachexia - Pipeline by Incyte Corporation, H2 2015
Cancer Cachexia - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
Cancer Cachexia - Pipeline by Novartis AG, H2 2015
Cancer Cachexia - Pipeline by Obexia AG, H2 2015
Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2015
Cancer Cachexia - Pipeline by Radius Health, Inc., H2 2015
Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H2 2015
Cancer Cachexia - Pipeline by Rhythm Pharmaceuticals, H2 2015
Cancer Cachexia - Pipeline by Vicus Therapeutics, LLC, H2 2015
Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Cancer Cachexia Therapeutics - Recent Pipeline Updates, H2 2015
Cancer Cachexia - Dormant Projects, H2 2015
Cancer Cachexia - Dormant Projects (Contd..1), H2 2015
Cancer Cachexia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Cancer Cachexia, H2 2015
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Cancer Cachexia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Cancer Cachexia - Pipeline Review, H2 2015’, provides an overview of the Cancer Cachexia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cancer Cachexia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cancer Cachexia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;